GMAB vs JNJ

For growth investors, Genmab A/S (GMAB) is the stronger pick with 30.

7% revenue growth year-over-year, versus 4. 3% for Johnson & Johnson (JNJ). Genmab A/S (GMAB) offers the better valuation at 14. 5x trailing P/E (23. 7x forward), making it the more compelling value choice. Analysts rate Genmab A/S (GMAB) a "Buy" — based on 17 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, Genmab A/S (GMAB) is the cheapest at 14.

5x versus Johnson & Johnson at 39. 0x. On forward P/E, Johnson & Johnson is actually cheaper at 19. 5x — notably different from the trailing picture, reflecting expected earnings growth. The PEG ratio (P/E divided by earnings growth rate) is the most growth-adjusted single valuation metric: Genmab A/S wins at 0. 82x versus Johnson & Johnson's 34. 64x — a PEG below 1. 0 traditionally signals the market is underpricing earnings growth.

Over the past 5 years, Johnson & Johnson (JNJ) delivered a total return of +49.

2%, compared to -24. 9% for Genmab A/S (GMAB). Over 10 years, the gap is even starker: JNJ returned +136. 8% versus GMAB's +85. 7%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Johnson & Johnson (JNJ) is the lower-risk stock at 0.

06β versus Genmab A/S's 0. 94β — meaning GMAB is approximately 1545% more volatile than JNJ relative to the S&P 500. On balance sheet safety, Genmab A/S (GMAB) carries a lower debt/equity ratio of 3% versus 51% for Johnson & Johnson — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Genmab A/S (GMAB) is pulling ahead at 30.

7% versus 4. 3% for Johnson & Johnson (JNJ). On earnings-per-share growth, the picture is similar: Genmab A/S grew EPS 83. 9% year-over-year, compared to -57. 8% for Johnson & Johnson. Over a 3-year CAGR, GMAB leads at 36. 8% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Genmab A/S (GMAB) is the more profitable company, earning 36.

4% net margin versus 15. 8% for Johnson & Johnson — meaning it keeps 36. 4% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: GMAB leads at 31. 1% versus 24. 9% for JNJ. At the gross margin level — before operating expenses — GMAB leads at 95. 4%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

The PEG ratio (forward P/E divided by expected earnings growth rate) is the most precise measure of undervaluation relative to growth potential.

By this metric, Genmab A/S (GMAB) is the more undervalued stock at a PEG of 0. 82x versus Johnson & Johnson's 34. 64x. A PEG below 1. 0 is traditionally considered the threshold for growth-adjusted undervaluation. On forward earnings alone, Johnson & Johnson (JNJ) trades at 19. 5x forward P/E versus 23. 7x for Genmab A/S — 4. 3x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for GMAB: 44. 9% to $39. 90.

In this comparison, JNJ (2.

2% yield) pays a dividend. GMAB does not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, Johnson & Johnson (JNJ) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.

06), 2. 2% yield, +136. 8% 10Y return). Both have compounded well over 10 years (JNJ: +136. 8%, GMAB: +85. 7%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: GMAB is a mid-cap high-growth stock; JNJ is a large-cap quality compounder stock. JNJ pays a dividend while GMAB does not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.